According to the research report titled ‘Global Cell and Gene Therapy Market 2022-2028’, available with MarketStudyReport, global cell and gene therapy market is anticipated to generate revenues worth USD 21,508 million by the year 2028, expanding at a 28.2% CAGR during the study period.

The rising prevalence of cancer, mounting funding for research and development activities, technological breakthroughs, and surging disposable income are some of the prominent factors driving the growth of global cell and gene therapy market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4973409/  

For those unaware, cell and gene therapy can treat, prevent, or even cure diseases as well as alleviate the underlying causes of both genetic and acquired disorders. Thus, increased pervasiveness of cancer and other chronic conditions have augmented the demand for this technology across the globe.

This global cell and gene therapy market report elaborates on the current business scenario, key development trends, and growth drivers. Besides, the report also provides an exclusive insight into market size, share, volume, competitive terrain, and growth rate along with the drastic effects of the COVID-19 crisis on this business sphere.

Apart from this, the research report offers crucial insights pertaining to several market segmentations such as product landscape, therapy type, therapeutic class, and regional bifurcation.

Based on the product landscape, the market is divided into zyntegio, zolgesma, yescarta, tecartus, strimveils, provenge, maci, luxturna, Kymriah, imlygic, gendicine, epicel, and others. Among these, the zolgesma segment captured the largest market share in 2021 and is likely to witness continuous growth in the ensuing years.

Moving on to the therapy type, the industry is bifurcated into gene therapy, gene-modified cell therapy, and cell therapy. As per therapeutic class, the market is fragmented into rare diseases, ophthalmology, oncology, neurology, and hematology.

The regional bifurcation of this business space extends to Asia Pacific, North America, Europe, and the rest of the world.

The major companies operating in global cell and gene therapy industry landscape are Vericel Corporation, Spark Therapeutics Inc., Shenzhen Sibiono GeneTech Co. Ltd., Shanghai Sunway Biotech Co. Ltd., Organogenesis Holdings Inc., Orchard Therapeutics plc, Novartis International AG, Human Stem Cells Institute PJSC, Gilead Sciences Inc., Dendreon Pharmaceuticals Inc., Bristol-Myers Squibb Company, bluebird bio-Inc., and Amgen Inc.